Matrix metalloproteinase inhibitors and cancer: trials and tribulations - PubMed (original) (raw)
Review
. 2002 Mar 29;295(5564):2387-92.
doi: 10.1126/science.1067100.
Affiliations
- PMID: 11923519
- DOI: 10.1126/science.1067100
Review
Matrix metalloproteinase inhibitors and cancer: trials and tribulations
Lisa M Coussens et al. Science. 2002.
Abstract
For at least 30 years, matrix metalloproteinases (MMPs) have been heralded as promising targets for cancer therapy on the basis of their massive up-regulation in malignant tissues and their unique ability to degrade all components of the extracellular matrix. Preclinical studies testing the efficacy of MMP suppression in tumor models were so compelling that synthetic metalloproteinase inhibitors (MPIs) were rapidly developed and routed into human clinical trials. The results of these trials have been disappointing. Here we review the studies that brought MPIs into clinical testing and discuss the design and outcome of the trials in light of new information about the cellular source, substrates, and mode of action of MMPs at different stages of tumor progression. The important lessons learned from the MPI experience may be of great value for future studies of MPIs and for cancer drug development in general.
Similar articles
- Matrix metalloproteinase inhibitors.
Ramnath N, Creaven PJ. Ramnath N, et al. Curr Oncol Rep. 2004 Mar;6(2):96-102. doi: 10.1007/s11912-004-0020-7. Curr Oncol Rep. 2004. PMID: 14751086 Review. - Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.
Overall CM, Kleifeld O. Overall CM, et al. Nat Rev Cancer. 2006 Mar;6(3):227-39. doi: 10.1038/nrc1821. Nat Rev Cancer. 2006. PMID: 16498445 Review. - Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?
Mannello F. Mannello F. Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):91-103. doi: 10.2174/157489206775246421. Recent Pat Anticancer Drug Discov. 2006. PMID: 18221029 Review. - Matrix metalloproteinase inhibitors.
Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Wojtowicz-Praga SM, et al. Invest New Drugs. 1997;15(1):61-75. doi: 10.1023/a:1005722729132. Invest New Drugs. 1997. PMID: 9195290 Review. - Progress in the development of matrix metalloproteinase inhibitors.
Tu G, Xu W, Huang H, Li S. Tu G, et al. Curr Med Chem. 2008;15(14):1388-95. doi: 10.2174/092986708784567680. Curr Med Chem. 2008. PMID: 18537616 Review.
Cited by
- Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer.
Hallett MA, Teng B, Hasegawa H, Schwab LP, Seagroves TN, Pourmotabbed T. Hallett MA, et al. Breast Cancer Res. 2013 Feb 13;15(1):R12. doi: 10.1186/bcr3385. Breast Cancer Res. 2013. PMID: 23407024 Free PMC article. - Harnessing the Systemic Biology of Functional Decline and Cachexia to Inform more Holistic Therapies for Incurable Cancers.
Willbanks A, Seals M, Karmali R, Roy I. Willbanks A, et al. Cancers (Basel). 2024 Jan 14;16(2):360. doi: 10.3390/cancers16020360. Cancers (Basel). 2024. PMID: 38254849 Free PMC article. Review. - Identification of specific Tie2 cleavage sites and therapeutic modulation in experimental sepsis.
Idowu TO, Etzrodt V, Seeliger B, Bolanos-Palmieri P, Thamm K, Haller H, David S. Idowu TO, et al. Elife. 2020 Aug 24;9:e59520. doi: 10.7554/eLife.59520. Elife. 2020. PMID: 32838837 Free PMC article. - Cytoskeletal stiffness, friction, and fluidity of cancer cell lines with different metastatic potential.
Coughlin MF, Bielenberg DR, Lenormand G, Marinkovic M, Waghorne CG, Zetter BR, Fredberg JJ. Coughlin MF, et al. Clin Exp Metastasis. 2013 Mar;30(3):237-50. doi: 10.1007/s10585-012-9531-z. Epub 2012 Sep 8. Clin Exp Metastasis. 2013. PMID: 22961212 Free PMC article. - Interactions among Lung Cancer Cells, Fibroblasts, and Macrophages in 3D Co-Cultures and the Impact on MMP-1 and VEGF Expression.
Liu XQ, Kiefl R, Roskopf C, Tian F, Huber RM. Liu XQ, et al. PLoS One. 2016 May 27;11(5):e0156268. doi: 10.1371/journal.pone.0156268. eCollection 2016. PLoS One. 2016. PMID: 27232698 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- CA72006/CA/NCI NIH HHS/United States
- P30CA68485/CA/NCI NIH HHS/United States
- P50CA90949/CA/NCI NIH HHS/United States
- R01CA60867/CA/NCI NIH HHS/United States
- R01CA84360/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical